Skip to search formSkip to main contentSkip to account menu

Anti-ErbB3 Monoclonal Antibody KTN3379

Known as: KTN3379 
A monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Anti-ErbB3… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma
BYL719 is a PI3K inhibitor that has demonstrated efficacy in the treatment of head and neck squamous cell carcinoma. BYL719… 
2017
2017
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
Head and neck squamous cell carcinoma (HNSCC) accounts for 3–5% of all tumor types and remains an unmet medical need with only… 
2016
2016
Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Purpose: Human papillomavirus (HPV) 16 plays an etiologic role in a growing subset of head and neck squamous cell carcinomas… 
2016
2016
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response
HER3/ERBB3 is a kinase-deficient member of the EGFR family receptor tyrosine kinases (RTK) that is broadly expressed and… 
2016
2016
Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted…
2501Background: KTN3379 is a fully human anti-ErbB3 antibody with YTE half-life extension engineering that uniquely binds domain… 
2016
2016
Effect of treatment of rectal cancer metastasis with intravitreal bevacizumab (Avastin) in patient with subretinal fluid and macular oedema: short-term follow-up
We describe the management of subretinal fluid and macular oedema due to colorectal cancer metastasis to the choroid using… 
2016
2016
Abstract 1196: Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN
ErbB3, the kinase-dead member of the EGFR/ErbB family, has been implicated as an oncogenic driver in a number of solid tumor… 
2015
2015
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration
Significance Many cancers are driven by aberrant activation of members of the EGF receptor (EGFR) family including ErbB2 (HER2… 
2015
2015
A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.
2598 Background: KTN3379 is a human monoclonal antibody against a unique epitope of human epidermal growth factor receptor-3… 
Review
2015
Review
2015
Abstract 1558: Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN
Aberrant regulation of the HER family of receptor tyrosine kinases (RTK) has proven to be a driver for promoting tumor growth and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License